Business
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES\nCanada NewsWire\nMONTREAL, Sept. 13, 2023\n\n\n\nSeventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22.Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total Enerzair and Atectura prescriptions for the 12 months ending July 31, 2023 exceeded 56,000, up 310% over July 31, 2022$4.5 million financing completed with Investissement Québec and insiders each investing $2.0 millionMONTREAL, Sept. 13, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2023.\n\n \n \n \n \n \n \n\n \nThird quarter 2023 Results & Highlights:\nRecord quarterly revenues of $14.1 million in Q3-23, compared to $6.1 million in Q3-22, up 132%, with Enerzair and Atecura up 234%.Record adjusted gross profit of $5.1 million in Q3-23 compared to $2.4 million in Q3-22, up 106%Q3-23 net loss of $5.8 million compared to $5.4 million in Q3-22,Q3-23 adjusted EBITDA loss of $2.5 million compared to a $3.5 million loss in Q3-22, a 28% reductionEnerzair and Atectura prescribing physicians reached 2,503 at the end of Q3-23, a 23% growth for the quarter and 221% increase year-over-yearTotal of 18,384 Enerzair and Atectura prescriptions during Q3-23, up 163% over Q3-22Total of 56,021 Enerzair and Atectura prescriptions over the last 12 months, up 310% year-over-year.\"Our record third quarter revenue and year to date results demonstrate our ability to generate sequential quarterly growth. Our key innovative products are well positioned in their respective market segments and we expect their organic growth trend to continue for many quarters to come\", said Steve Saviuk, Chief Executive Officer. \"Enerzair and Atectura are leading the way for...